Viz.ai has received clearance from the U.S. Food and Drug Administration (FDA) for an algorithm to automatically calculate right-to-left ventricle diameter (RV/LV ratios) of the heart on CT scans.
The algorithm is a new component of the company's Viz PE platform, which is used to identify suspected central and segmental pulmonary emboli in under two minutes, the company said. With the integration of the RV/LV algorithm, the software now includes an automated assessment of potential right ventricle dilation.
Viz PE now includes both detection of clots in the lungs and degree of strain on the right heart, which will enable clinicians to quickly triage patients and treat them appropriately, Viz.ai said.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
